CAMBRIDGE, Mass., Aug. 1, 2023
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage
biopharmaceutical company focused on creating precisely
targeted therapies for clinically proven kinase targets in cancer,
today announced that James Porter,
Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will
participate in the following August investor conferences:
- 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023 in NYC (one-on-one
meetings only)
- Canaccord Genuity 43rd Annual Growth Conference on
Wednesday, August 9, 2023 at
8:00 a.m. ET in Boston
A live webcast of the fireside chat at the Canaccord Genuity
43rd Annual Growth Conference will be available in the
investor section of the company's website at www.nuvalent.com, and
archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for patients
with cancer, designed to overcome the limitations of existing
therapies for clinically proven kinase targets. Leveraging deep
expertise in chemistry and structure-based drug design, we develop
innovative small molecules that have the potential to overcome
resistance, minimize adverse events, address brain metastases, and
drive more durable responses. Nuvalent is advancing a robust
pipeline with parallel lead programs in ROS1-positive and
ALK-positive non-small cell lung cancer (NSCLC), a program in
HER2 Exon 20 insertion-positive cancers, and multiple
discovery-stage research programs. We routinely post information
that may be important to investors on our website
at www.nuvalent.com. Follow us on Twitter (@nuvalent)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-upcoming-august-investor-conferences-301889900.html
SOURCE Nuvalent, Inc.